The role of Ki-67 proliferation index vis-à-vis Oncotype DX

Autor:	Raquel Aloyz, Solmaz Sahebjam, Victor Cohen, Cristiano Ferrario, Wilson H. Miller, D. Pilavdzic, Nathaniel Bouganim, Lawrence Panasci, M. Brisson
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty medicine.diagnostic_test biology Proliferation index Adjuvant chemotherapy business.industry Recurrence score medicine.disease Node negative Predictive factor Breast cancer Internal medicine Ki-67 medicine biology.protein Oncotype DX business
Zdroj:	Journal of Clinical Oncology. 29:e11055-e11055
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.e11055
Popis:	e11055 Background: Most newly diagnosed patients with invasive breast cancer have node negative disease. A key question in management of these patients is the risk/benefit ratio of adjuvant chemotherapy. Several microarray tests have been developed and are currently used to help identifying the patients who will benefit from adjuvant chemotherapy. Ki 67 proliferation index is less expensive and has been used as a prognostic and predictive factor in node positive breast cancer and neoadjuvant setting. Methods: Forty five cases of T1-2 N0 M0 (ER positive, HER2/neu negative) breast cancer were reviewed. Oncotype Dx results were available for all patients. Tumor specimens were stained for Ki 67. Results: The median of Ki 67 index was 17 (range 2-90). The median Oncotype recurrence score was 17 (range 7-60). There was a strong linear correlation between Ki67 index and Oncotype recurrence score (correlation coefficient= 0.74, P value= 0.000). This correlation was stronger in tumors with Ki 67 proliferation inde...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::794603f495266ac4254a1d743622b819 https://doi.org/10.1200/jco.2011.29.15_suppl.e11055 Zobrazit plný text záznamu